Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Phathom Pharmaceuticals Inc (NQ: PHAT ) 11.18 -0.93 (-7.68%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,482,025 Open 11.90 Bid (Size) 11.21 (8) Ask (Size) 11.60 (1) Prev. Close 12.11 Today's Range 10.80 - 12.18 52wk Range 6.065 - 17.02 Shares Outstanding 43,614,075 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults Today 8:00 EDT From Phathom Pharmaceuticals Via GlobeNewswire Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now June 09, 2024 Each of the following seven heavily-shorted stocks may have what it takes to become one of the next big short squeeze stocks. Via InvestorPlace Performance YTD +21.92% +21.92% 1 Month -5.81% -5.81% 3 Month +17.93% +17.93% 6 Month +47.11% +47.11% 1 Year -20.31% -20.31% More News Read More Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze June 07, 2024 Via InvestorPlace Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences May 28, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Preview: Phathom Pharmaceuticals's Earnings March 06, 2024 Via Benzinga Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting May 15, 2024 From Phathom Pharmaceuticals Via GlobeNewswire The 3 Best Healthcare Stocks to Buy in May 2024 May 10, 2024 Via InvestorPlace PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 April 29, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid” March 26, 2024 From Phathom Pharmaceuticals Via GlobeNewswire PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 March 07, 2024 Via InvestorPlace Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 February 29, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday February 20, 2024 Via Benzinga Topics Stocks Exposures US Equities Earnings Scheduled For March 7, 2024 March 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session February 16, 2024 Via Benzinga Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients February 13, 2024 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From Phathom Pharmaceuticals Via GlobeNewswire "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales January 05, 2024 Via Benzinga Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital December 14, 2023 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD December 06, 2023 From Phathom Pharmaceuticals Via GlobeNewswire Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn November 28, 2023 From Phathom Pharmaceuticals Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
